Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
Pragmatica-Lung
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
- NCT05633602 ↗
- Active, not recruiting
- SWOG Cancer Research Network
- Deep
We haven't built an HCP commentary report on Pragmatica-Lung (pembrolizumab and ramucirumab in Recurrent Lung Non-Small Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Pragmatica-Lung so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 15 | |
| YouTube | 8 | |
| Podcasts | 7 |
The trial
ClinicalTrials.gov- Official title
- Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
- Interventions
- Chemotherapy; Pembrolizumab; Ramucirumab
- Arms
- ARM A (standard of care chemotherapy) · Active comparator
- ARM B (ramucirumab, pembrolizumab) · Experimental
- Enrollment
- 838
- Primary outcomes
- Overall survival
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
- Start
- Mar 14, 2023
- Primary completion
- Nov 26, 2025
- Results posted
- No
- Registry record
- NCT05633602 · updated Apr 17, 2026